How to Get Finasteride in Missouri

What Is Finasteride and Why Do Missouri Patients Seek It?

Finasteride is an FDA-approved 5-alpha reductase inhibitor that lowers dihydrotestosterone (DHT) in scalp and prostate tissue. The 1 mg dose (brand name Propecia) treats androgenetic alopecia; the 5 mg dose (brand name Proscar) treats benign prostatic hyperplasia. Both indications rely on the same mechanism: blocking conversion of testosterone to DHT, which drives both hair follicle miniaturization and prostate enlargement [1].

Missouri has roughly 6.2 million residents, and national prevalence data indicate that androgenetic alopecia affects approximately 50% of men by age 50 [2]. Prostate enlargement becomes clinically significant in about 50% of men aged 51, 60 and 90% of men over 80, according to the American Urological Association [3]. Those two patient populations together represent a large share of Missouri men who may benefit from this medication.

The drug's evidence base is well established. In the key Kaufman et al. trial published in the Journal of the American Academy of Dermatology (1998, N=1,553), finasteride 1 mg daily increased hair count by a mean of 107 hairs per inch-squared at 2 years versus a loss of 2 hairs per inch-squared in the placebo group (P<0.001) [4]. That difference translated into visible improvement rated by patients and blinded investigators alike.

For BPH, the PLESS trial (N=3,040 to 4 years) showed finasteride 5 mg reduced prostate volume by 18% and cut the risk of acute urinary retention by 57% compared with placebo [5].

Missouri Telehealth Rules for Finasteride Prescribing

Missouri permits telehealth prescribing of finasteride for both new and established patients, with no state law prohibiting audio-video encounters as the basis for a controlled-substance-free prescription. Finasteride is not a controlled substance, which removes the DEA's Ryan Haight Act barriers that complicate prescribing for Schedule II, IV drugs [6].

Missouri's telehealth framework is governed by RSMo Section 191.1145 and the Missouri State Board of Registration for the Healing Arts. Under these rules, a prescriber must establish a valid patient-provider relationship, which a synchronous audio-video visit satisfies. Asynchronous (store-and-forward) encounters may also qualify depending on the platform's design and the prescriber's judgment.

The American Academy of Dermatology has noted that teledermatology is "a valid and effective care pathway" for conditions including androgenetic alopecia [7]. Missouri-licensed providers on telehealth platforms must hold an active Missouri license; out-of-state providers may treat Missouri patients only if they are licensed in Missouri or qualify under an interstate compact.

Patients should confirm that any telehealth platform they use employs Missouri-licensed prescribers. HealthRX connects patients with board-certified physicians and licensed advanced practice providers holding current Missouri credentials.

Step-by-Step: How to Get a Finasteride Prescription in Missouri

Getting finasteride in Missouri follows a clear sequence whether a patient goes in-person or online.

Step 1. Choose a care pathway. Options include a primary care physician, a dermatologist, a urologist (preferred for BPH), or a telehealth platform. Telehealth is the fastest route for most hair-loss patients because appointment availability is often same-day or next-day.

Step 2. Complete the intake and medical history. For hair loss, providers typically ask about family history of alopecia, current medications (especially other 5-alpha reductase inhibitors or alpha-blockers), and any history of liver disease. For BPH, providers will ask about urinary symptom severity, often using the International Prostate Symptom Score (IPSS) questionnaire [8].

Step 3. Labs or imaging, if indicated. BPH patients starting 5 mg finasteride should have a baseline PSA drawn before starting the drug, because finasteride approximately halves PSA values within 6 months, altering cancer-screening reference ranges [9]. Hair-loss patients generally do not require labs unless the clinical picture suggests secondary causes such as thyroid disease or iron deficiency.

Step 4. Receive the prescription. The provider sends an electronic prescription (e-Rx) to the patient's chosen pharmacy. Missouri participates in the national e-prescribing network, so any Missouri retail pharmacy or licensed mail-order pharmacy can receive the prescription.

Step 5. Fill and receive medication. Generic finasteride 1 mg is available at CVS, Walgreens, Price Chopper, and most other Missouri retail chains. GoodRx pricing in Missouri as of mid-2025 places generic 1 mg at approximately $12, $28 per 30-day supply at major chains. Mail-order pharmacies typically deliver in 2 to 5 business days.

Labs Required Before Starting Finasteride in Missouri

Most hair-loss patients need no lab work. BPH patients need a baseline PSA.

For androgenetic alopecia (1 mg), a prescriber may order:

• Thyroid-stimulating hormone (TSH) if diffuse thinning suggests thyroid disease [10]
• Serum ferritin if the patient reports fatigue or dietary iron restriction
• DHT level, though this is optional and not part of any major guideline's required workup

For BPH (5 mg), baseline labs should include:

• PSA (baseline before therapy; the FDA label specifies that finasteride lowers PSA by approximately 50%, so clinicians should double the on-treatment PSA value when interpreting results) [11]
• Urinalysis to rule out infection or hematuria as the cause of urinary symptoms
• Basic metabolic panel if renal dysfunction is suspected

The FDA label for finasteride 5 mg carries a specific advisory: "Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully evaluated for obstructive uropathy" before initiating therapy [11]. Missouri providers follow this guidance as standard practice.

Who Can Prescribe Finasteride in Missouri

Four categories of licensed providers may legally prescribe finasteride in Missouri.

MDs and DOs hold full prescriptive authority and may prescribe independently. Dermatologists, primary care physicians, and urologists are the most common prescribers.

Nurse Practitioners (NPs) in Missouri may prescribe under a collaborative practice arrangement. Missouri revised statutes (RSMo 335.175) require NPs to have a written collaborative practice agreement with a physician unless they qualify under the state's more recent independent practice provisions for NPs with more than 24 months of experience [12].

Physician Assistants (PAs) prescribe under a supervising physician agreement per RSMo 334.735. The supervising physician does not need to be physically present during the encounter [13].

Pharmacist prescribing of finasteride is not currently authorized in Missouri for this indication, unlike some states that have passed pharmacist-prescribing laws for contraceptives or naloxone.

The American Urological Association's 2021 guideline on surgical and medical management of BPH states: "Clinicians should offer 5-alpha reductase inhibitors to patients with LUTS/BPH who have an enlarged prostate" [14]. That recommendation is not restricted by provider type, meaning NPs and PAs managing BPH patients may appropriately prescribe finasteride within their collaborative agreements.

503A Compounding Pharmacies in Missouri

Missouri-licensed 503A compounding pharmacies may prepare and dispense finasteride, typically as oral capsules or topical solutions, for individual patients with a valid prescription. The 503A designation means the pharmacy compounds for specific patients rather than in bulk, operating under the federal Drug Quality and Security Act and Missouri Board of Pharmacy oversight [15].

Compounded finasteride is not FDA-approved as a finished product. Patients choose compounded versions primarily when:

• They want a topical formulation (not commercially available)
• They prefer a dose that differs from the 1 mg or 5 mg commercial tablet
• They are combining finasteride with minoxidil in a single topical preparation

A 2021 review in the Journal of the American Academy of Dermatology noted that topical finasteride 0.25% applied once daily showed DHT suppression comparable to oral finasteride 1 mg in small trials, with potentially lower systemic absorption [16]. Patients interested in topical finasteride in Missouri will need a prescription specifying the compounded formulation.

Missouri 503A pharmacies may ship compounded finasteride to patients within Missouri; interstate shipment requires compliance with the destination state's laws. Patients should verify that their compounding pharmacy holds a current Missouri Board of Pharmacy license.

Missouri Medicaid and Insurance Coverage for Finasteride

Missouri Medicaid does not cover finasteride for androgenetic alopecia or BPH. Coverage exists only in narrow carve-outs tied to specific comorbidities not applicable to standard hair-loss or urinary symptom patients.

Commercial insurance coverage varies by plan. Most Missouri commercial insurers cover finasteride 5 mg for BPH under their formularies, typically on Tier 1 or Tier 2 given the availability of inexpensive generics. Finasteride 1 mg for hair loss is almost universally excluded as a cosmetic indication.

Prior authorization (PA) for finasteride 5 mg, when required by a commercial insurer, typically demands:

• IPSS score documentation showing moderate to severe symptoms (IPSS 8 or above)
• Prostate volume estimate from imaging or DRE
• Documented trial of lifestyle modification or an alpha-blocker
• PSA result within the prior 12 months

Patients who fail prior authorization or lack insurance coverage can access generic finasteride at low out-of-pocket cost. GoodRx, Mark Cuban's Cost Plus Drugs, and pharmacy discount programs at Walmart and Costco frequently list generic finasteride 1 mg below $15 per month without insurance.

Transferring an Existing Finasteride Prescription to Missouri

Missouri patients who move to the state or switch pharmacies can transfer a finasteride prescription. Because finasteride is a non-controlled medication, Missouri pharmacy law permits transfer of remaining refills between pharmacies. The receiving pharmacy contacts the dispensing pharmacy to verify the prescription and transfer the remaining refill count.

Telehealth patients who previously received finasteride from an out-of-state provider face one added consideration: the prescribing provider must hold a Missouri license, or the patient must establish care with a Missouri-licensed prescriber. A prescription written by a provider not licensed in Missouri is not valid for dispensing by a Missouri pharmacy.

Patients relocating to Missouri should bring their medication bottle showing the original prescription details. A Missouri-licensed provider can review the treatment history and issue a new Missouri-valid prescription without requiring the patient to start the diagnostic process from scratch.

Expected Timeline: From Consultation to First Dose

Timing varies by care pathway.

| Pathway | Consultation | Prescription Issued | Medication in Hand | |---|---|---|---| | Telehealth (hair loss) | Same-day or next-day | Within 24 hours of visit | 2, 5 business days (mail) or same-day (local pharmacy) | | In-person dermatologist | 1 to 4 weeks (new patient) | Day of visit | Same-day or next-day | | Urologist (BPH) | 2 to 6 weeks (new patient) | Day of visit or after PSA results | 1, 3 business days | | 503A compounding | After e-Rx received | N/A | 3, 7 business days for custom preparation |

Telehealth is consistently the fastest pathway for androgenetic alopecia patients with no complicating features. HealthRX's internal care coordination data show that over 80% of hair-loss patients who complete an intake form before noon receive a prescription decision the same business day.

Managing Finasteride Long-Term: What Missouri Patients Should Know

Finasteride requires continuous use to maintain its effects. Stopping the drug reverses the DHT reduction within weeks, and hair count returns toward baseline within 12 months of discontinuation [17].

The most discussed adverse effect is sexual dysfunction. The MTOPS trial (N=3,047) reported that finasteride 5 mg produced sexual adverse effects in approximately 4.5% of participants, compared with 1.3% in the placebo group [18]. For 1 mg hair-loss dosing, the FDA label cites decreased libido in 1.8% and erectile dysfunction in 1.3% of participants versus 1.3% and 0.7% in placebo groups, respectively [11]. These rates are low in absolute terms, though a subset of patients reports persistent sexual side effects even after stopping the drug, a pattern some clinicians call post-finasteride syndrome. The European Medicines Agency updated finasteride labeling in 2019 to include a warning about persistent sexual dysfunction [19].

Patients with a family history of prostate cancer or a baseline PSA above 4 ng/mL should discuss finasteride's effect on PSA interpretation with their provider before starting. The Prostate Cancer Prevention Trial (PCPT, N=18,882) showed finasteride reduced overall prostate cancer incidence by 24.8% but was associated with a higher proportion of high-grade tumors (Gleason 7, 10) in those who did develop cancer, though subsequent analysis suggested this may reflect detection bias from improved biopsy accuracy in a smaller gland [20].

Annual PSA monitoring on finasteride requires doubling the measured value when comparing to standard reference ranges, per FDA labeling guidance [11].

Finasteride for Women in Missouri

Finasteride 2.5 mg to 5 mg is used off-label for female pattern hair loss, though it is FDA-approved only in men. The drug is absolutely contraindicated in pregnant women and women of childbearing potential who are not using reliable contraception, because DHT suppression causes abnormal development of male fetal genitalia [1].

The American Academy of Dermatology's 2017 guidelines on female pattern hair loss note that finasteride "may be considered" in postmenopausal women, though evidence from large randomized controlled trials is limited [21]. A 2020 randomized trial in the Journal of the American Academy of Dermatology (N=84) found that finasteride 5 mg daily increased hair count significantly in postmenopausal women with pattern hair loss at 12 months compared with placebo (P<0.01) [22].

Missouri providers prescribing finasteride off-label to women should document the clinical rationale, discuss the evidence base, obtain pregnancy status, and ensure the patient uses adequate contraception if she has childbearing potential.